Holly Taylor, PhD, MPH

Department of Bioethics, NIH Clinical Center





Disclaimer

The views expressed in this talk are my own.

They do not represent the position or policy of the NIH, DHHS, or US government

Overview

Good study design is key to conduct of an ethical study.



Overview

 "Researchers have a fundamental obligation to plan, design, and conduct studies with honesty, truthfulness and integrity – values demonstrated by how researchers observe, record and interpret their work." (Research Design, p.6)

Ethical Requirements

- Collaborative Partnerships
- Social or scientific value
- Scientific validity
- Fair subject selection
- Favorable risk-benefit ratio
- Independent review
- Informed consent
- Respect for participants

Source: Emanuel, Wendler and Grady (2008)





- Basics
 - Observational Research
 - Descriptive
 - Retrospective or prospective
 - Experimental Research
 - Interventional
 - Usually prospective



Basics

- Experimental Design
 - Manipulation
 - Ability to manipulate at least one variable
 - Control
 - Ability to prevent outside factors from influencing study outcome
 - Randomization
 - Random, unbiased selection and assignment of the research sample



Basics

- Quasi Experimental Design
 - Manipulation
 - Ability to manipulate at least one variable
 - Control
 - Ability to prevent outside factors from influencing study outcome
 - Randomization
 - Random, unbiased selection and assignment of the research sample



- Social Value
 - Does the Project have social value?
 - If no, study cannot go forward

Source: Emanuel, Wendler and Grady (2008)



- Scientific Validity
 - Is the study design valid?
 - Sample size
 - Too small?
 - Too large?



- Scientific Validity
 - Is the study design valid?
 - Is there *uncertainty* about potential benefit of the proposed intervention?
 - If no, study cannot go forward as designed
 - If yes, is randomized controlled trial (RCT) appropriate design
 - » Is randomization to a placebo acceptable?

Source: Emanuel, Wendler and Grady (2008)





Study Design: RCT

- Randomized Controlled Trial
 - Indifference among community of clinicians about which treatment superior
 - "Equipoise"
 - Controlled
 - Blinding
 - Randomized
 - Placebo or active control
 - Standard of Care



Placebo

- What is it?
 - Pill that looks just like the drug but doesn't contain any medicine.



- Why it is included in study?
 - Want to find out if the real medicine works like they hope it does. Need to compare people who get the real medicine to those don't to see if the medicine works.



Placebo

- When is it ethically acceptable to include a placebo?
 - When no good standard treatment exists
 - If a standard treatment exists, then
 - When placebos are "additive"
 - Standard plus placebo vs. Standard plus new intervention
 - When the medical condition in question is not serious
 - When being off of standard medication for length of trial will not cause serious, irreversible harm



Placebo

- When is placebo ethically important?
 Why not just have 'no intervention' arm?
 - When outcome can be subjective (pain, emotion, endurance)
 - When risk behaviors may be affected by thinking one received experimental tx vs. nothing (e.g., HIV vaccines)
 - When follow up for data collection could be affected (need to keep getting pills so return)



Ethical Principles: Study Design

- Independent review
 - Peer review
- Design executed as described in approved protocol
 - Oversight
- Study findings must be reported completely and promptly
 - During trial
 - After trial

Source: Joffe and Troug (2008)





Types of Trials

- Clinical Trials
 - Phase 1
 - Phase 2
 - Phase 3
 - Phase 4







Phase 1

70

Phase 2

For every 100 Phase I Trials testing novel interventions, 6-7 make it To FDA approval for marketing.

23



Phase 3



6-7

Phase 4/Market

Source: FDA (2022)





94% of trials conducted at the NIH Clinical Center early phase trials.



Phase 1 (toxicity) 299 studies (37%)

Tests a new medication or treatment for the first time in a small group of people (20–80) to evaluate its safety, determine a safe closage range and identify side effects.



Phase 2 (activity) 473 studies (57%)

Medication or treatment is given to a larger group of people (100–300) to see if it is effective and further evaluate its safety.



Phase 3 (efficacy) 41 studies (5%)

Medication or treatment is given to large groups of people (3,000 or more) to confirm its effectiveness, monitor side effects, compare it with commonly used treatments and collect information to ensure it is used safely.



Phase 4 (safety) 11 studies (1%)

Conducted after the drug or treatment has been marketed to collect information about the effect of the medication or treatment in various populations and to determine any side effects from long-term use.

Source: NIH Clinical Center Data Report (2021)





- Clinical Trials
 - Phase 1 (n=20-80)
 - First in human trial
 - Safety
 - Dosage
 - Maximum Tolerated Dose (MTD)



- Clinical Trials
 - Phase 2 (20-300)
 - First dose, one lower than MTD
 - Assess biologic effect
 - Adverse events





- Clinical Trials
 - Phase 3 (300-3000+)
 - Based on results of Phase II
 - Effectiveness
 - Safety
 - Risk/benefit for adoption in clinical practice



- Clinical Trials
 - Phase 4
 - Post marketing trial
 - Long term safety
 - Celebrex
 - Avandia



Oversight: DMC

- Oversight
 - Data Monitoring Committees (DMCs)
 - Protect subjects from previously unknown adverse events
 - Avoid unnecessarily prolonged exposure to an inferior treatment
 - Interim analysis
 - Stopping rules



Summary

Good study design is key to conduct of an ethical study.